arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Curaleaf Holdings, Inc.

CURLF
— Price unavailable
Materials ·Medicinal Chemicals & Botanical Products ·USMedicinal Chemicals & Botanical Products
13 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Bearish
auto_awesome

Analytical Summary

Curaleaf Holdings, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth 10.9% ↗
Op. Margin 0.8% ↘
ROIC 0.3% ↗
FCF / Share $0.02
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity 0.74
info Valuation on last close.

13-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$352.65M
↑ +10.9% —
Net Income Profit after all expenses
$69.80M
— 0.0% —
Operating Margin Operating profit as % of sales
0.8%
↓ -32.8% 33th
FCF / Share Free cash flow per share
$0.02
↓ -87.7% —
Long-Term Debt Long-term obligations
$629.48M
↑ +2.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
31
Returns ↓
23
Financial Health →
45
Cash Quality
15

bar_chart Data from SEC EDGAR XBRL filings

Synced 6 days ago 7 years · 13 quarters